Research Summary

Patient-Reported Outcomes Improve with Clinically Meaningful Scalp Hair Regrowth in Alopecia Areata

Edited by:
Kate Young

Key Highlights

  • Patients achieving SALT20 or SALT10 responses at Week 24 reported greater improvements across emotional, functional, and satisfaction measures.
  • Responders demonstrated larger reductions in emotional symptoms and activity limitations from Weeks 24–48.
  • Satisfaction with hair growth and perceived global improvement remained consistently higher among responders.
  • Mental health outcomes, including HADS and SF-36v2 Malnutrition Care Scores, improved more in responders.

In a post hoc analysis published in the Journal of Dermatological Treatment, investigators examined the association between scalp hair regrowth and patient-reported outcomes (PROs) among individuals with alopecia areata (AA). Using data from the ALLEGRO-2b/3 trial, investigators evaluated whether achieving clinically meaningful regrowth translated into improvements in emotional well-being, functional limitations, and other domains important to patients.

The analysis included 650 participants from the ALLEGRO-2b/3 randomized, double-blind, placebo-controlled trial. Responders were defined as achieving a SALT score ≤20 (SALT20) at Week 24; those achieving ≤10 (SALT10) were assessed in sensitivity analyses. PROs were evaluated from Weeks 24–48 using 6 measures:

  • Alopecia Areata Patient Priority Outcomes (AAPPO)
  • Patient Global Impression of Change (PGI-C)
  • Patient Satisfaction with Hair Growth (P-Sat)
  • Work Productivity and Activity Impairment (WPAI-AA)
  • SF-36v2
  • Hospital Anxiety and Depression Scale (HADS)

Analyses were treatment-agnostic, with pooled responder and non-responder groups.

Study Findings

Responders demonstrated significantly greater improvements in AAPPO emotional symptoms at all time points, with least squares mean differences (LSMDs) favoring SALT20 responders at Week 24 (−0.56; 95% CI, −0.72 to −0.40) and Week 48 (−0.67; 95% CI, −0.83 to −0.51). Activity limitation scores also improved more in responders, with a Week-48 LSMD of −0.30 (95% CI, −0.41 to −0.19). Across individual AAPPO items, odds ratios consistently favored responders.

At Week 24, 97.37% of SALT20 responders reported being “greatly” or “moderately improved” on PGI-C compared with 26.92% of non-responders (OR, 96.05; 95% CI, 30.20–305.47). High perceived improvement persisted through Week 48. Satisfaction with hair growth (P-Sat) similarly favored responders, with >97% satisfaction reported across items at Week 24 and maintained through Week 48.

Responders reported greater improvement in work and activity impairment. At Week 48, LSMDs favored SALT20 responders for presenteeism (−6.25; 95% CI, −10.70 to −1.80), work impairment (−6.35; 95% CI, −10.90 to −1.80), and activity impairment (−7.23; 95% CI, −11.36 to −3.10). No significant differences were observed for absenteeism.

SALT20 responders experienced larger improvements in SF-36v2 mental component scores, with a Week-48 LSMD of 2.69 (95% CI, 1.14–4.24). HADS scores also favored responders, with Week-48 Anxiety LSMD −0.80 (95% CI, −1.41 to −0.20) and Depression LSMD −0.60 (95% CI, −1.10 to −0.11).

Clinical Implications

According to the authors, clinically meaningful scalp hair regrowth was associated with improvements across multiple PRO domains, including emotional burden, functional limitations, satisfaction, and mental health. The investigators noted that responder benefits were observed regardless of treatment assignment and emphasized the complex but meaningful relationship between clinical regrowth and patient-perceived outcomes. Study limitations included potential selection bias from missing assessments and variability in psychological responses not fully captured by modeling.

Expert Commentary

“Our study shows an association of perceived treatment benefits with clinically meaningful hair regrowth, thereby providing valuable insights into the complexity of this relationship,” the researchers concluded. “These findings contribute to the AA treatment paradigm and highlight the ongoing need for close collaboration between patients and clinicians in setting treatment expectations and monitoring goals.”

Reference
Law EH, Hanson KA, Harries M, Korver D, Sherif B, Chirila C. Patient-reported outcome improvements following scalp hair regrowth among patients with Alopecia Areata: analysis of the ALLEGRO-2b/3 trial. J Dermatolog Treat. 2025;36(1):2460577. doi:10.1080/09546634.2025.2460577.